Get the app
US › Healthcare

EyePoint, Inc (EYPT)

US · Healthcare · Biotechnology

$3.99+15.65%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$507,000
Revenue YoY
-90.5%
Net profit
$-94.5M
EPS
$-1.09
EPS estimate
$-0.92
Net margin
-18,633.1%

EPS came in at -1.09 against a street estimate of -0.92 — a miss of 18.5%.

Key statistics

Market cap
$354.6M
Forward P/E
6.2
P/B
2.20
Book value
$0.40
EPS (TTM)
$-3.73
52-week high
$19.11
52-week low
$3.95
50-day MA
$10.21
200-day MA
$13.49
Beta
1.64

Analyst view

Analysts rate EyePoint, Inc a strong buy (13 buy, 0 hold, 0 sell out of 13) with an average price target of $25.91.

Shareholding

Insiders
3.52%
Institutions
117.94%

Largest institutional holders

FundStake
Suvretta Capital Management, LLC9.62%
Cormorant Asset Management, LLC9.59%
BlackRock Inc8.33%
Federated Hermes Inc6.59%
Franklin Templeton Inc5.86%
Adage Capital Partners Gp LLC5.60%
HHG PLC4.18%
Vanguard Capital Management, LLC4.13%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for EyePoint, Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.